Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Bristol-Myers Squibb |
---|---|
Information provided by: | Bristol-Myers Squibb |
ClinicalTrials.gov Identifier: | NCT00103701 |
The purpose of this clinical research study is to understand the safety and efficacy of BMS-354825 in patients with chronic, accelerated, or blast phase chronic myelogenous leukemia (CML) or Philadelphia positive acute lymphoblastic leukemia (ALL) who are resistant to or intolerant of imatinib mesylate (Gleevec).
Condition | Intervention | Phase |
---|---|---|
Leukemia, Myeloid, Chronic-Phase Leukemia, Lymphoblastic, Acute, Philadelphia-Positive |
Drug: Dasatinib |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety Study |
Official Title: | Phase I Study of BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Drug: Dasatinib
Tablets, Oral, 15- 240 mg, Once or twice daily, 0-3 years depending on response.
|
Ages Eligible for Study: | 14 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |
Local Institution | |
Los Angeles, California, United States | |
United States, Texas | |
Local Institution | |
Houston, Texas, United States |
Study Director: | Bristol-Myers Squibb | Bristol-Myers Squibb |
Study ID Numbers: | CA180-002 |
Study First Received: | February 14, 2005 |
Last Updated: | June 27, 2008 |
ClinicalTrials.gov Identifier: | NCT00103701 |
Health Authority: | United States: Food and Drug Administration |
Chronic myelogenous leukemia (CML) chronic, accelerated, blast phase Philadelphia chromosome positive acute (Ph+ALL) |
Philadelphia Chromosome Blast Crisis Leukemia, Lymphoid Immunoproliferative Disorders Precursor Cell Lymphoblastic Leukemia-Lymphoma Chronic myelogenous leukemia Hematologic Diseases Myeloproliferative Disorders Leukemia, Myeloid |
Leukemia, Myeloid, Chronic-Phase Lymphatic Diseases Leukemia Dasatinib Leukemia, Myelogenous, Chronic, BCR-ABL Positive Bone Marrow Diseases Lymphoproliferative Disorders Lymphoma |
Neoplastic Processes Neoplasms Pathologic Processes |
Neoplasms by Histologic Type Immune System Diseases Cell Transformation, Neoplastic |